

PRESS RELEASE

The National Drug Authority (NDA) is mandated by the National Drug Policy and Authority Act, Chapter 206, Section 40, to regulate drug related clinical trials in Uganda.

Following a stakeholders 'meeting held in Anisha Hall, Hotel Equatoria on July 18th 2007 to discuss draft guidelines for conduct of clinical trials in Uganda, a new fee structure was presented. It was agreed by all members present that it should be left to NDA Board to determine fees structures from time to time.

In July 2011 the NDA Board approved a new fees structure for Clinical Trial Applications basing on the need to effectively regulate clinical trials in Uganda as is the case elsewhere in the region.

Having received a number of complaints from stakeholders about lack of knowledge on this new fees structure, NDA officially communicated the fees change in a stakeholders' meeting that was held on December 15th 2011 at Orange Hall, Hotel Africana.

NDA therefore informs all researchers and other stakeholders involved in drug related clinical trials that the new fees structure will take effect from 1st July 2012.

Below is the New Approved Fees Structure

Stage of clinical trial	Product	Fees (USD)
Phase 1	Registered or unregistered	2500
Phase ,II,III	New investigational product (Unregistered)	4000
Phase ,II,III	Known product (Registered)	3000
Phase IV		1000
Others	including Device, Nutritional supplement, herbal and (always with registered product),public health products	1000
Amendments		200
FEES FOR FIELD TRIAL FEES (VETERINARY)		
All phases	ARCARICIDES	1000

National Drug Authority
Management